EWM
TXMD icon

Edge Wealth Management’s TherapeuticsMD TXMD Stock Holding History

Edge Wealth Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Hold
0
– -$1K – 424
2021
Q4 		– Hold
0
– – – 491
2021
Q3 		– Hold
0
– – – 509
2021
Q2 		– Hold
0
– – – 419
2021
Q1 		– Hold
0
– – – 381
2020
Q4 		– Hold
0
– – – 331

Other funds holding TXMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Edge Wealth Management's TXMD Position: Q1 2022 in Review

Edge Wealth Management sold out of TherapeuticsMD (TXMD) in Q1 2022, closing a stake of 17 shares — an estimated $1K sold.

Edge Wealth Management first reported a position in TXMD in Q3 2017 and held it in 15 quarters. The position peaked at $125K in Q4 2017. 124 funds tracked by Wall St. Rank hold TXMD as of Q1 2022.

  • Edge Wealth Management reported no remaining TherapeuticsMD position as of Q1 2022 after selling out during the quarter.
  • Edge Wealth Management sold 17 TherapeuticsMD shares in Q1 2022, an estimated $1K.
  • Edge Wealth Management first reported a position in TherapeuticsMD in Q3 2017 and held it in 15 quarters.
  • Edge Wealth Management's TherapeuticsMD position peaked at $125K in Q4 2017.
  • 124 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2022.

Based on Edge Wealth Management's 13F filing for Q1 2022, filed 14 Apr 2022.